(Health Korea News / Yoo Ji-in) Ilead BMS, a new drug research and development company of Ildong Pharmaceutical Group, disclosed research results on new drug candidates in the field of heart disease at an international academic conference.
ILead BMS participated in the ‘Antifibrotic Drug Development Summit (AFDD)’ held in Boston, USA from the 19th to the 21st and presented non-clinical research data on its new drug candidate ‘IL21120038’ in poster format. announced.
‘IL21120038’ is an anti-fibrotic new drug candidate based on a small molecule compound that acts on CXCR7 (CXC chemokine receptor 7), which is closely involved in causing fibrosis and inflammation in biological tissues among the receptors for chemokine, one of the signaling proteins related to immunity. It is a substance. CXCR7 is known to play an important role in suppressing the death of myocardial cells when ischemia or damage occurs in the heart.
‘IL21120038’ is a CXCR7 agonist drug and has high binding selectivity to CXCR7, which is prominently expressed in cardiomyocytes. It shows anti-inflammatory and anti-fibrotic effects by removing CXCL12 (CXC motif chemokine 12), an inflammation-causing factor.
According to the poster presentation, the results of non-clinical research on a myocardial infarction model using laboratory rats showed that ‘IL21120038’ significantly reduced the infarct area in the left ventricle. The levels of CK-MB3 (creatine kinase-MB3) and cTnI (cardiac troponin I), indicators of heart damage, were also found to be significantly lowered. In addition to increasing cardiac output, the effect of alleviating inflammation and fibrosis was confirmed. In a test comparing it with Entresto (ingredients: sacubitril and valsartan), an existing drug widely used to treat cardiovascular diseases such as heart failure, ‘IL21120038’ showed a superior improvement effect.
Through non-clinical research, iLead BMS has confirmed its potential as an innovative new drug (first-in-class) to treat various heart diseases caused by fibrosis, such as ischemic heart disease, arrhythmia, and heart failure. We plan to quickly meet all requirements necessary for applying for clinical trial (IND) approval related to ‘IL21120038’, including safety evaluation (GLP) testing.
Through various non-clinical studies related to CXCR7 agonists, Ilead BMS has confirmed the possibility of treating lung and liver fibrosis in addition to heart disease. Research results were presented at the American Thoracic Society (ATS) and the European Association for the Study of the Liver Diseases (EASL) held this year. The company plans to participate in the JP Morgan Healthcare Conference scheduled to be held next year and discuss commercialization, including joint development and out-licensing, with global pharmaceutical companies.
Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited
Source: www.hkn24.com
